LQDA Stock Analysis: Buy, Sell, or Hold?
LQDA - Liquidia Corporation Common Stock
$59.30
1.71 (2.97%)
▲
5d:
+40.26%
30d:
+47.81%
90d:
+51.9%
WAIT
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
LQDA is down 5.5% this week, but smart money is accumulating calls. Top strike: $40 2026-07-17 with 3,571 OI. Call ratio: 92% View Scanner →
Strength: 6.9/10
Get Alerted When LQDA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
6 traders called LQDA this week
86% bullish • 1 bearish
86% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR BETTER ENTRY: LQDA is 24.3% above its trading range ($47.72). Market expects -0.2% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
⏸️ WAIT FOR BETTER ENTRY: LQDA is 24.3% above its trading range ($47.72). Market expects -0.2% annual growth, but current price leaves little margin for error. While momentum could continue, risk/reward favors waiting for a pullback.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$116.54
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$72.36
18.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: LQDA is currently trading at $59.30, which is considered extended relative to its 30-day fair value range of $34.96 to $47.72. The stock's valuation (Forward PE: 11.4) is in line with its historical norms (11.5). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, LQDA is in a uptrend. The price is approaching resistance at $58.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LQDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, LQDA is in a uptrend. The price is approaching resistance at $58.62. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LQDA has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$34.96 -
$47.72
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.6%
Protect Your Profits
LQDA is technically overbought (RSI 87). Consider hedging now to protect against a potential pullback while keeping your upside.
View Profit Protection PlanAll Signals
- BEARISH: Price significantly overextended (+24.3% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($60.62)
- WARNING: Recommendation downgraded due to 24.3% overvaluation
Trading Range Analysis
30-Day Trading Range
$34.96 -
$47.72
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$37.45
Resistance Level
$58.62
Current Trend
Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.40
Wall Street Target
$60.63
(+2.2%)
Revenue Growth (YoY)
4158.5%
Profit Margin
7.7%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
11.4 vs 11.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$59.18
(0%)
2-Year Target
$59.06
(0%)
3-Year Target
$58.94
(-1%)
3-Yr Target (if PE normalizes)
(PE: 11→12)
$59.49
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 50.4%)
$387.10
(+553%)
Base:
(SPY PE: 11.4, Growth: 50.4%)
$200.14
(+238%)
Bear:
(PE: 9.7, Growth: 50.4%)
$170.12
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Forward PE: 33.33 | Forward EPS (Implied): $1.78
Bull Case
$71.60
(+21%)
Analyst growth 15.0%, PE expands to 35.0
Base Case
$59.30
(0%)
Market implied 0.0%, PE stable at 33.3
Bear Case
$45.36
(-24%)
Severe decline -15.0%, PE contracts to 30.0
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.4 to 11.5
Stabilization Target:
$59.85
(+0.9%)
PE Expansion Potential:
+0.9%
Share & Embed Analysis
Last updated: May 14, 2026 6:32 PM ET
Data refreshes hourly during market hours. Next update: 7:32 PM
Data refreshes hourly during market hours. Next update: 7:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LQDA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
20
Sells
Net
INSIDERS SELLING
Recent Transactions
Roger Jeffs
SELL
18839 shares
2026-04-17
Michael Kaseta
SELL
139390 shares
2026-04-15
Roger Jeffs
SELL
25000 shares
2026-04-15
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
Advanced LQDA Option Strategies
Professional options setups generated by AI based on today's LQDA price and gamma walls.